A Phase 3 interventional study of Abemaciclib and Anastrozole in Breast Cancer, sponsored by Eli Lilly and Company. Active, not recruiting at 45 sites in 4 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.
Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 7th largest by enrollment, is one of 5 that started in 2016, is one of 11 in phase 3, reaches primary completion later than 2 of the 33 other live ones, and was the 9th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
Japanese Foundation for Cancer Research · Sites in Japan
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Mridula George, MD · Sites in United States
Ages 60+ · Women only
By country, each count listing its studies:
abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, abemaciclib is the treatment under test here. Read study by study →
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 29 · Phase 3 11 · Phase 4 8
First in 2014; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 463 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 120 across the 55 interventional studies. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 55 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
88 studies in Breast Neoplasms by Eli Lilly and Company: 7 open now, 22 under way, 8 of them phase 3. Of 61 finished, 40 (66%) have results posted.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 14th largest by enrollment of the 80 interventional ones that give a count, is one of 6 that started in 2016, is one of 16 in phase 3, reaches primary completion later than 2 of the 21 other live ones, and was the 56th registered.
Eli Lilly and Company’s Breast Neoplasms studies by the year they started, since 1998.
6 of the studies testing abemaciclib in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06341621Phase 3Fudan UniversityChemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib | 2027-02-25 |
| NCT05305924The Methodist Hospital Research InstituteFulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer | 2026-12-01 |
| NCT06207734Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestDiscontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer | 2027-01-10 |
| NCT04614194University of Texas Southwestern Medical CenterSingle Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib | 2027-04-15 |
| NCT04305834City of Hope Medical CenterAbemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. | 2027-05-21 |
Add all 6 to your calendar (.ics) → With an account.
Among the 55 studies testing abemaciclib in Breast Neoplasms, from their registry updates:
Among Eli Lilly and Company’s 88 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the efficacy of the study drug abemaciclib in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locoregionally recurrent or metastatic breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have a diagnosis of HR+, - breast cancer. Although not required as a protocol procedure, disease should be considered for whenever possible to reassess hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status if clinically indicated.
(2a) Have locoregionally recurrent disease not amenable to resection or radiation therapy with curative intent or metastatic disease.
(2b) Have locoregionally recurrent disease not amenable to resection or radiation therapy with curative intent or metastatic disease.
Have status defined as meeting at least 1 of the following:
Have 1 of the following, as defined by the (RECIST) v1.1:
Have adequate organ function, including:
Hematologic: (ANC) ≥1.5 × 109/Liter (L),
≥100 × 109/L, and ≥8 g/deciliter (dL). Participants may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator; however, initial study drug treatment must not begin earlier than the day after the erythrocyte transfusion.
Hepatic: Total ≤1.5 times the (ULN) and (ALT) and aspartate aminotransferase (AST)
≤3.0 times ULN (or ALT and AST ≤5 times ULN if liver metastases are present).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Abemaciclib given orally every 12 hours (Q12H) plus anastrozole or letrozole given orally every 24 hours (Q24H) on days 1 to 28 of a 28 day cycle. Participants receiving benefit may continue until disease progression.
Drug: Abemaciclib · Drug: Anastrozole · Drug: Letrozole
Placebo given orally Q12H plus anastrozole or letrozole given orally Q24H on days 1 to 28 of a 28 day cycle. Participants receiving benefit may continue until disease progression.
Drug: Anastrozole · Drug: Letrozole · Drug: Placebo
Abemaciclib given orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant intramuscularly (IM) on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond. Participants receiving benefit may continue until disease progression.
Drug: Abemaciclib · Drug: Fulvestrant
Placebo given orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant IM on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond. Participants receiving benefit may continue until disease progression.
Drug: Placebo · Drug: Fulvestrant
Administered orally
Also known as: LY2835219
Administered orally
Administered orally
Administered orally
Administered intramuscularly
Progression Free Survival (PFS) (Abemaciclib + NSAI & Placebo NSAI)
Progression-free survival time was measured from randomization until the date of objective progression as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), or death from any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Patients who have neither progressed nor died were censored at the day of their last radiographic tumor assessment, if available, or date of randomization if no post-baseline radiographic assessment is available.
Time frame: Randomization to Measured Progressive Disease or Death (up to 26 Months)
Progression Free Survival (PFS) (Abemaciclib + Fulvestrant and Placebo + Fulvestrant Arms)
Progression-free survival time was measured from randomization until the date of objective progression as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), or death from any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Patients who have neither progressed nor died were censored at the day of their last radiographic tumor assessment, if available, or date of randomization if no post-baseline radiographic assessment is available.
Time frame: Randomization to Measured Progressive Disease or Death (up to 26 Months)
Overall Survival (OS)
Time frame: Randomization to Date of Death from Any Cause (Estimated up to 38 Months)
Percentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]
Objective response rate is the percentage of participants with a BOR of CR or PR as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.
Time frame: Randomization to Measured Progressive Disease (up to 26 Months)
Duration of Response (DoR)
Time frame: Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up to 38 Months)
Percentage of Participants Who Exhibit Stable Disease (SD) or CR or PR [Disease Control Rate (DCR)]
Disease control rate (DCR) is the percentage of participants with a best overall response of CR, PR or SD as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Randomization to Measured Progressive Disease (up to 26 Months)
Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months [Clinical Benefit Rate (CBR)]
Clinical benefit rate (CBR) is the percentage of participants with a BOR of CR or PR, or SD for at least 6 months. CR is defined as the disappearance of all target and non-target lesions \& no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Randomization to Measured Progressive Disease (up to 26 Months)
Change From Randomization in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)
consists of 30 items covered by 1 of 3 dimensions: 1. Global health status/quality of life (2 items) with scores ranging from 1 (Very Poor) to 7 (Excellent). 2. Functional scales (15 total items addressing either physical, role, emotional, cognitive, or social functioning), each item scores ranging from 1 (not at all) to 4 (very much) 3. Symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, or financial impact), each item scores ranging from 1 (not at all) to 4 (very much). Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function/QOL or higher levels of symptom burden.
Time frame: Baseline through 19 Months
Pharmacokinetics (PK): Area Under the Concentration Curve of Abemaciclib, Its Metabolites (M2 & M20)
Pharmacokinetics (PK): Area Under the Concentration Curve of Abemaciclib and its Metabolites LSN2839567 (M2) \& LSN3106726 (M20) was reported. C=Cycle, D=day;
Time frame: C1D1 post dose, C2D1 post dose, C3D1 predose, C4D1 predose
| Milestone | Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) | Placebo + NSAI | Abemaciclib + Fulvestrant | Placebo + Fulvestrant |
|---|---|---|---|---|
| Started | 207 | 99 | 104 | 53 |
| Completed | 89 | 60 | 50 | 39 |
| Not completed | 118 | 39 | 54 | 14 |
| Withdrew: Lost to follow-up | 1 | 4 | 0 | 1 |
| Withdrew: On study treatment at study conclusion | 114 | 34 | 54 | 13 |
| Withdrew: Withdrawal by subject | 3 | 1 | 0 | 0 |
Progression-free survival time was measured from randomization until the date of objective progression as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), or death from any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Patients who have neither progressed nor died were censored at the day of their last radiographic tumor assessment, if available, or date of randomization if no post-baseline radiographic assessment is available.
| Months | Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) | Placebo + NSAI |
|---|---|---|
| Progression Free Survival (PFS) (Abemaciclib + NSAI & Placebo NSAI) | NA (22.32 to NA) | 14.73 (11.21 to 18.87) |
Progression-free survival time was measured from randomization until the date of objective progression as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), or death from any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Patients who have neither progressed nor died were censored at the day of their last radiographic tumor assessment, if available, or date of randomization if no post-baseline radiographic assessment is available.
| Months | Abemaciclib + Fulvestrant | Placebo + Fulvestrant |
|---|---|---|
| Progression Free Survival (PFS) (Abemaciclib + Fulvestrant and Placebo + Fulvestrant Arms) | 11.47 (9.53 to NA) | 5.59 (3.65 to 7.69) |
Results for this outcome have not been posted.
Objective response rate is the percentage of participants with a BOR of CR or PR as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.
| percentage of participants | Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) | Placebo + NSAI | Abemaciclib + Fulvestrant | Placebo + Fulvestrant |
|---|---|---|---|---|
| Percentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)] | 56.0 (49.3 to 62.8) | 30.3 (21.3 to 39.4) | 38.5 (29.1 to 47.8) | 7.5 (0.4 to 14.7) |
Results for this outcome have not been posted.
Disease control rate (DCR) is the percentage of participants with a best overall response of CR, PR or SD as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
| percentage of participants | Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) | Placebo + NSAI | Abemaciclib + Fulvestrant | Placebo + Fulvestrant |
|---|---|---|---|---|
| Percentage of Participants Who Exhibit Stable Disease (SD) or CR or PR [Disease Control Rate (DCR)] | 91.3 (87.5 to 95.1) | 82.8 (75.4 to 90.3) | 92.3 (87.2 to 97.4) | 69.8 (57.5 to 82.2) |
Clinical benefit rate (CBR) is the percentage of participants with a BOR of CR or PR, or SD for at least 6 months. CR is defined as the disappearance of all target and non-target lesions \& no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
| percentage of participants | Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) | Placebo + NSAI | Abemaciclib + Fulvestrant | Placebo + Fulvestrant |
|---|---|---|---|---|
| Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months [Clinical Benefit Rate (CBR)] | 82.6 (77.4 to 87.8) | 62.6 (53.1 to 72.2) | 77.9 (69.9 to 85.9) | 45.3 (31.9 to 58.7) |
consists of 30 items covered by 1 of 3 dimensions: 1. Global health status/quality of life (2 items) with scores ranging from 1 (Very Poor) to 7 (Excellent). 2. Functional scales (15 total items addressing either physical, role, emotional, cognitive, or social functioning), each item scores ranging from 1 (not at all) to 4 (very much) 3. Symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, or financial impact), each item scores ranging from 1 (not at all) to 4 (very much). Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function/QOL or higher levels of symptom burden.
| score on a scale | Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) | Placebo + NSAI | Abemaciclib + Fulvestrant | Placebo + Fulvestrant |
|---|---|---|---|---|
| Global Health Status | 2.38 ± 0.99 | 4.26 ± 1.47 | -0.35 ± 1.41 | 3.12 ± 2.07 |
| Functional Scales - Physical Functioning | -0.78 ± 0.82 | -0.01 ± 1.21 | -1.11 ± 1.06 | -2.70 ± 1.54 |
| Functional Scales - Role Functioning | -1.69 ± 1.20 | -1.38 ± 1.79 | -3.76 ± 1.35 | -2.04 ± 1.95 |
| Functional Scales - Emotional Functioning | 1.57 ± 0.98 | -0.10 ± 1.44 | 0.43 ± 1.27 | 0.18 ± 1.85 |
| Functional Scales - Cognitive Functioning | -2.89 ± 0.90 | -0.72 ± 1.35 | -3.52 ± 1.35 | -1.10 ± 1.96 |
| Functional Scales - Social Functioning | -2.45 ± 1.19 | -1.57 ± 1.75 | -2.03 ± 1.71 | -2.67 ± 2.44 |
| Symptom Scales - Fatigue | 1.63 ± 0.95 | 0.06 ± 1.40 | 4.19 ± 1.44 | 1.46 ± 2.08 |
| Symptom Scales - Nausea and Vomiting | 0.62 ± 0.60 | -0.33 ± 0.88 | 4.26 ± 1.10 | 1.67 ± 1.65 |
| Symptom Scales - Pain | -5.44 ± 0.91 | -4.90 ± 1.35 | -2.82 ± 1.36 | -0.17 ± 2.01 |
| Symptom Scales - Dyspnoea | 2.51 ± 1.02 | 0.35 ± 1.53 | -1.66 ± 1.27 | 0.83 ± 1.92 |
| Symptom Scales - Insomnia | -0.87 ± 1.07 | -0.05 ± 1.60 | 1.53 ± 1.59 | -0.44 ± 2.42 |
| Symptom Scales - Appetite | 4.19 ± 0.97 | -1.47 ± 1.44 | 8.67 ± 1.63 | 1.21 ± 2.42 |
| Symptom Scales - Constipation | -3.05 ± 0.98 | -1.49 ± 1.46 | -1.63 ± 1.31 | 0.65 ± 1.88 |
| Symptom Scales - Diarrhoea | 15.72 ± 0.85 | -0.10 ± 1.27 | 16.03 ± 1.26 | -1.80 ± 1.95 |
| Symptom Scales - Financial Difficulties | -3.02 ± 1.65 | -1.27 ± 2.46 | -6.36 ± 1.76 | -9.35 ± 2.59 |
Pharmacokinetics (PK): Area Under the Concentration Curve of Abemaciclib and its Metabolites LSN2839567 (M2) \& LSN3106726 (M20) was reported. C=Cycle, D=day;
| Nanogram*hour per Millilitre (ng*h/mL) | Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) | Abemaciclib + Fulvestrant |
|---|---|---|
| Abemaciclib | 2720 ± 40 | 2740 ± 57 |
| LSN2839567 (M2) | 1080 ± 84 | 861 ± 120 |
| LSN3106726 (M20) | 1970 ± 81 | 1570 ± 110 |
Collected over Up to 28 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) | 20/205 (9.8%) | 40/205 (19.5%) | 204/205 (99.5%) |
| Placebo + NSAI | 10/99 (10.1%) | 9/99 (9.1%) | 85/99 (85.9%) |
| Abemaciclib + Fulvestrant | 8/104 (7.7%) | 16/104 (15.4%) | 103/104 (99%) |
| Placebo + Fulvestrant | 9/53 (17%) | 4/53 (7.5%) | 39/53 (73.6%) |
| Event | Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) | Placebo + NSAI | Abemaciclib + Fulvestrant | Placebo + Fulvestrant |
|---|---|---|---|---|
| Lung infectionInfections and infestations | 6/205 | 1/99 | 2/104 | 1/53 |
| VomitingGastrointestinal disorders | 4/205 | 0/99 | 0/104 | 0/53 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 4/205 | 1/99 | 0/104 | 0/53 |
| EmbolismVascular disorders | 2/205 | 0/99 | 2/104 | 0/53 |
| PyrexiaGeneral disorders | 0/205 | 0/99 | 0/104 | 1/53 |
| Bile duct obstructionHepatobiliary disorders | 0/205 | 0/99 | 0/104 | 1/53 |
| HypokalaemiaMetabolism and nutrition disorders | 2/205 | 0/99 | 1/104 | 1/53 |
| Facial nerve disorderNervous system disorders | 0/205 | 0/99 | 0/104 | 1/53 |
| Transient ischaemic attackNervous system disorders | 0/205 | 0/99 | 0/104 | 1/53 |
| CholecystitisHepatobiliary disorders | 3/205 | 0/99 | 1/104 | 0/53 |
| Event | Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) | Placebo + NSAI | Abemaciclib + Fulvestrant | Placebo + Fulvestrant |
|---|---|---|---|---|
| White blood cell count decreasedInvestigations | 156/205 | 27/99 | 86/104 | 12/53 |
| Neutrophil count decreasedInvestigations | 164/205 | 20/99 | 84/104 | 10/53 |
| DiarrhoeaGastrointestinal disorders | 164/205 | 15/99 | 82/104 | 5/53 |
| AnaemiaBlood and lymphatic system disorders | 127/205 | 20/99 | 73/104 | 8/53 |
| Platelet count decreasedInvestigations | 90/205 | 7/99 | 43/104 | 5/53 |
| Alanine aminotransferase increasedInvestigations | 71/205 | 23/99 | 36/104 | 12/53 |
| Aspartate aminotransferase increasedInvestigations | 71/205 | 21/99 | 32/104 | 14/53 |
| FatigueGeneral disorders | 60/205 | 25/99 | 24/104 | 8/53 |
| NauseaGastrointestinal disorders | 54/205 | 19/99 | 19/104 | 9/53 |
| Decreased appetiteMetabolism and nutrition disorders | 48/205 | 11/99 | 23/104 | 6/53 |
All randomized participants.
| Age, Continuous(years) | Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) | Placebo + NSAI | Abemaciclib + Fulvestrant | Placebo + Fulvestrant | Total |
|---|---|---|---|---|---|
| Mean | 56.4 ± 10.8 | 55.5 ± 9.8 | 59.7 ± 8.5 | 58.2 ± 10.3 | 57.1 ± 10.1 |
| Sex: Female, Male(Participants) | Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) | Placebo + NSAI | Abemaciclib + Fulvestrant | Placebo + Fulvestrant | Total |
|---|---|---|---|---|---|
| Female | 207 | 99 | 104 | 53 | 463 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) | Placebo + NSAI | Abemaciclib + Fulvestrant | Placebo + Fulvestrant | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 207 | 99 | 104 | 53 | 463 |
| Race (NIH/OMB)(Participants) | Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) | Placebo + NSAI | Abemaciclib + Fulvestrant | Placebo + Fulvestrant | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 182 | 89 | 94 | 48 | 413 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 1 | 1 | 5 |
| White | 24 | 8 | 8 | 4 | 44 |
| More than one race | 0 | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) | Placebo + NSAI | Abemaciclib + Fulvestrant | Placebo + Fulvestrant | Total |
|---|---|---|---|---|---|
| China | 164 | 82 | 89 | 45 | 380 |
| Brazil | 21 | 8 | 10 | 5 | 44 |
| South Africa | 4 | 2 | 0 | 1 | 7 |
| India | 18 | 7 | 5 | 2 | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2016 to primary completion in Mar 2019, 27 months.
Results were first posted in Mar 2020, 1 year after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 27 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abemaciclib · Letrozole